Pasithea Therapeutics (KTTA) Cost of Revenue (2022)
Pasithea Therapeutics (KTTA) has disclosed Cost of Revenue for 1 consecutive years, with -$1308.0 as the latest value for Q4 2022.
- Quarterly Cost of Revenue changed N/A to -$1308.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $113195.0 through Dec 2022, changed N/A year-over-year, with the annual reading at $113195.0 for FY2022, 555.25% up from the prior year.
- Cost of Revenue hit -$1308.0 in Q4 2022 for Pasithea Therapeutics, down from $86465.0 in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $86465.0 in Q3 2022 to a low of -$1308.0 in Q4 2022.